Baird analyst Joel Beatty raised the firm’s price target on Intra-Cellular to $103 from $83 and keeps an Outperform rating on the shares. The firm increased its price target after successful topline ph3 results for Caplyta in major depressive disorder (MDD) as they view the efficacy as at or above investor expectations, and safety as generally in line with expectations.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
- Intra-Cellular Advances Depression Treatment with Lumateperone
- Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
- Needham remains positive on Intra-Cellular ahead of Caplyta readouts
- Intra-Cellular Therapies Announces Executive Leadership Changes
